In response to tumor-secreted factors such as IL-6-stimulated thrombopoietin, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor, platelet production can increase more than 20-fold [10] and platelets from patients with metastatic cancers show significantly increased aggregation in response to tumor-derived agonists [11]. This evidence concerns the gene CSF3 and neoplasm.